Literature DB >> 25878944

An Association between Carpal Tunnel Syndrome and Migraine Headaches-National Health Interview Survey, 2010.

Huay-Zong Law1, Bardia Amirlak1, Jonathan Cheng1, Douglas M Sammer1.   

Abstract

BACKGROUND: Migraine headaches have not historically been considered a compression neuropathy. Recent studies suggest that some migraines are successfully treated by targeted peripheral nerve decompression. Other compression neuropathies have previously been associated with one another. The goal of this study is to evaluate whether an association exists between migraines and carpal tunnel syndrome (CTS), the most common compression neuropathy.
METHODS: Data from 25,880 respondents of the cross-sectional 2010 National Health Interview Survey were used to calculate nationally representative prevalence estimates and 95% confidence intervals (95% CIs) of CTS and migraine headaches. Logistic regression was used to calculate adjusted odds ratios (aORs) and 95% CI for the degree of association between migraines and CTS after controlling for known demographic and health-related factors.
RESULTS: CTS was associated with older age, female gender, obesity, diabetes, and smoking. CTS was less common in Hispanics and Asians. Migraine was associated with younger age, female gender, obesity, diabetes, and current smoking. Migraine was less common in Asians. Migraine prevalence was 34% in those with CTS compared with 16% in those without CTS (aOR, 2.60; 95% CI, 2.16-3.13). CTS prevalence in patients with migraine headache was 8% compared with 3% in those without migraine headache (aOR, 2.67; 95% CI, 2.22-3.22).
CONCLUSIONS: This study is the first to demonstrate an association between CTS and migraine headache. Longitudinal and genetic studies with physician verification of migraine headaches and CTS are needed to further define this association.

Entities:  

Year:  2015        PMID: 25878944      PMCID: PMC4387155          DOI: 10.1097/GOX.0000000000000257

Source DB:  PubMed          Journal:  Plast Reconstr Surg Glob Open        ISSN: 2169-7574


  85 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  An anatomical study of the lesser occipital nerve and its potential compression points: implications for surgical treatment of migraine headaches.

Authors:  Michelle Lee; Matthew Brown; Kyle Chepla; Haruko Okada; James Gatherwright; Ali Totonchi; Brendan Alleyne; Samantha Zwiebel; David Kurlander; Bahman Guyuron
Journal:  Plast Reconstr Surg       Date:  2013-12       Impact factor: 4.730

3.  Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression.

Authors:  Jeffrey E Janis; Arjun Dhanik; Jessica H Howard
Journal:  Plast Reconstr Surg       Date:  2011-07       Impact factor: 4.730

Review 4.  The cost of migraine and its treatment.

Authors:  Lawrence D Goldberg
Journal:  Am J Manag Care       Date:  2005-06       Impact factor: 2.229

5.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

6.  A socioeconomic analysis of surgical treatment of migraine headaches.

Authors:  Carey Faber; Ryan M Garcia; Janine Davis; Bahman Guyuron
Journal:  Plast Reconstr Surg       Date:  2012-04       Impact factor: 4.730

7.  Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS).

Authors:  Andrew Blumenfeld; Avi Ashkenazi; Brian Grosberg; Uri Napchan; Samer Narouze; Bob Nett; Traci DePalma; Barbara Rosenthal; Stewart Tepper; Richard B Lipton
Journal:  Headache       Date:  2010-06       Impact factor: 5.887

8.  Obesity is a risk factor for transformed migraine but not chronic tension-type headache.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

9.  Comprehensive surgical treatment of migraine headaches.

Authors:  Bahman Guyuron; Jennifer S Kriegler; Janine Davis; Saeid B Amini
Journal:  Plast Reconstr Surg       Date:  2005-01       Impact factor: 4.730

Review 10.  Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review.

Authors:  Andrew Blumenfeld; Avi Ashkenazi; Uri Napchan; Steven D Bender; Brad C Klein; Randall Berliner; Jessica Ailani; Jack Schim; Deborah I Friedman; Larry Charleston; William B Young; Carrie E Robertson; David W Dodick; Stephen D Silberstein; Matthew S Robbins
Journal:  Headache       Date:  2013-02-13       Impact factor: 5.887

View more
  3 in total

1.  Topiramate-induced Neuropathy Mimicking Carpal Tunnel Syndrome: A Case Report.

Authors:  Jigar S Gandhi; Michael Rivlin
Journal:  Arch Bone Jt Surg       Date:  2018-01

2.  Quantitative Models for Prediction of Cumulative Trauma Disorders Applied to the Maquiladora Industry.

Authors:  Melissa Airem Cázares-Manríquez; Claudia Camargo-Wilson; Ricardo Vardasca; Jorge Luis García-Alcaraz; Jesús Everardo Olguín-Tiznado; Juan Andrés López-Barreras; Blanca Rosa García-Rivera
Journal:  Int J Environ Res Public Health       Date:  2021-04-06       Impact factor: 3.390

Review 3.  Comorbidities of primary headache disorders: a literature review with meta-analysis.

Authors:  Valeria Caponnetto; Manuela Deodato; Paolo Martelletti; Alberto Raggi; Micaela Robotti; Maria Koutsokera; Valeria Pozzilli; Cristina Galati; Giovanna Nocera; Eleonora De Matteis; Gioacchino De Vanna; Emanuela Fellini; Gleni Halili; Daniele Martinelli; Gabriele Nalli; Serena Serratore; Irene Tramacere
Journal:  J Headache Pain       Date:  2021-07-14       Impact factor: 7.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.